PHAT - Phathom submits additional data to FDA for esophagitis candidate
2023-08-21 09:48:10 ET
More on Phathom Pharmaceuticals
- Phathom Pharma: Time To Take Profits (Rating Downgrade)
- Phathom resubmits vonoprazan application for esophagitis to FDA, announces stock offering
- Phathom gains as Evercore ISI upgrades on potential vonoprazan approval
- Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals
For further details see:
Phathom submits additional data to FDA for esophagitis candidate